Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTAÔ – formerly FIBRILLEXÔ) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration and European Medicines Agency. Tramiprosate (ALZHEMEDÔ), for the treatment of Alzheimer’s disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRILÔ), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. ( www.neurochem.com )
Neurochem Inc.
275 Armand-Frappier Blvd.
Laval, Québec H7V 4A7
Canada
Tel: (450) 680-4500
Fax: (450) 680-4501